Welcome to our dedicated page for Ibex SEC filings (Ticker: IBEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IBEX Limited SEC filings document the company's public-company reporting for its business process outsourcing and AI-powered customer experience operations. Recent 8-K filings furnish quarterly and annual financial results, operating outlook updates, press-release exhibits, and Inline XBRL cover data for a Bermuda registrant that identifies as an emerging growth company.
IBEX proxy and governance filings cover annual general meeting matters, board structure, director elections, authority to fill board vacancies, long-term incentive plan approvals, auditor appointment votes, and committee governance. Material-event filings also document board committee changes and other corporate governance disclosures tied to the company's Nasdaq-listed reporting obligations.
IBEX Ltd director Patrick McGinnis sold shares in a routine insider transaction. On May 28, 2026, he completed an open-market sale of 1,030 Common Shares at $31.69 per share. After this sale, he continues to hold 5,833 Common Shares directly.
IBEX Ltd Chief Financial Officer Taylor C. Greenwald reported two share transactions in Common Shares. On May 22, 2026, he sold 964 shares in an open-market sale at $32.02 per share and acquired 3,333 shares from earned performance-based stock units. After these transactions, he directly owned 62,230 Common Shares.
IBEX Limited announced that its board of directors has authorized a share repurchase program allowing the company to buy back up to $20 million of its common stock. The program begins on May 14, 2026 and may run for up to one year.
Repurchases may occur through open market purchases, privately negotiated deals, block trades, or other lawful methods, subject to market conditions and compliance with SEC Rules 10b-18 and 10b5-1. The company plans to fund repurchases using its existing cash balance and free cash flow. The board may adjust, suspend, or discontinue the program at any time, and IBEX is not obligated to repurchase a specific number of shares.
IBEX Ltd Chief Executive Officer Robert Thomas Dechant sold 7,800 common shares in an open-market transaction. The shares were sold at a weighted average price of $30.4996 per share, with individual trades executed between $30.37 and $30.88. After this sale, Dechant directly holds 285,606 IBEX common shares.
IBEX Ltd Chief Sales and CS Officer Bruce Neil Dawson reported two open-market sales of Common Shares. On May 11, 2026, he sold 3,129 shares at a weighted average price of $32.8038 per share. On May 12, 2026, he sold 15,260 shares at a weighted average price of $31.1156. After these transactions, he directly owns 61,895 Common Shares.
IBEX Ltd reports a proposed sale of 14,523 shares of Common Stock tied to the vesting of a PSU grant on 09/30/2025. The filing lists this sale under equity compensation and notes recent open-market dispositions by Robert Thomas Dechant of 6,000 shares on each of several dates in February 2026.
The notice identifies J.P. Morgan Securities LLC as the broker and classifies the shares as Common Stock to be sold on Nasdaq. The filing is a routine regulatory notice of intended resale following equity compensation vesting.
IBEX Ltd filed a Form 144 reporting a proposed resale of 15,260 shares of Common Stock. The filing references a PSU Grant by Issuer with a PSU vest date of 02/06/2026. The notice also lists prior sales of 3,129 shares on 05/11/2026.
The filing is a Form 144 notice related to proposed sales of Common Stock for IBEX. The excerpt lists broker/dealer Wells Fargo Clearing Services and shows transaction-related figures including 3,129, 102,477.50, and 13,389,116 with a date of 05/11/2026. The excerpt also records two issuer RSU vesting entries dated 10/02/2025 (2,269 shares) and 07/01/2025 (860 shares).
IBEX Limited delivered strong growth for the quarter ended March 31, 2026. Revenue reached $164.4 million, up 16.8% from the prior-year quarter, driven by HealthTech, Retail & E-commerce, Travel, Technology and Other verticals, partly offset by lower Telecommunications revenue.
Net income rose to $13.3 million, a 27.3% increase, with diluted earnings per share climbing to $0.89 from $0.73. For the nine-month period, revenue grew 16.7% to $479.8 million, while net income increased 37.8% to $37.6 million and diluted EPS improved to $2.54. Margin gains were helped by higher contributions from offshore delivery centers and growth in higher-margin digital acquisition services, while the company continued investing in AI-enabled CX solutions and new capacity offshore.